

Experiment Number: 20601 - 04

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 12/03/2014

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

F1_M3

NTP Study Number:

C20601

Lock Date:

06/22/2011

Cage Range:

ALL

Date Range:

ALL

Reasons For Removal:

25022 ACCK

25021 TSAC

25020 NATD

25019 MSAC

Removal Date Range:

ALL

Treatment Groups:

Include ALL

Study Gender:

Both

TDMSE Version:

3.0.2.2_002

PWG Approval Date:

NONE

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
------------------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	60	60	60	60
Early Deaths				
Accidentally Killed		1		
Moribund Sacrifice	7	12	15	26
Natural Death	5	7	8	7
Survivors				
Terminal Sacrifice	38	30	27	17
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Hepatocolangiocarcinoma, Metastatic, Liver	1 (2%)			
Gallbladder	(44)	(41)	(38)	(40)
Intestine Large, Cecum	(46)	(45)	(45)	(47)
Adenoma		2 (4%)		
Intestine Large, Colon	(48)	(45)	(47)	(48)
Intestine Large, Rectum	(47)	(42)	(45)	(48)
Intestine Small, Duodenum	(45)	(45)	(42)	(46)
Adenoma	2 (4%)			
Intestine Small, Ileum	(46)	(44)	(43)	(48)
Adenoma			1 (2%)	
Intestine Small, Jejunum	(46)	(44)	(42)	(48)
Carcinoma	1 (2%)	1 (2%)		1 (2%)
Liver	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Cholangiocarcinoma	1 (2%)			
Cholangioma				1 (2%)
Hemangiosarcoma				1 (2%)
Hemangiosarcoma, Metastatic, Spleen			1 (2%)	
Hepatoblastoma	2 (4%)	1 (2%)		4 (8%)
Hepatocellular Adenoma	12 (24%)	15 (30%)	22 (45%)	15 (30%)
Hepatocellular Adenoma, Multiple	18 (36%)	16 (32%)	14 (29%)	18 (36%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Hepatocellular Carcinoma	13 (26%)	17 (34%)	7 (14%)	15 (30%)
Hepatocellular Carcinoma, Multiple	2 (4%)	6 (12%)	7 (14%)	5 (10%)
Hepatocholangiocarcinoma	1 (2%)			
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Mesentery	(7)	(4)	(4)	(5)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (25%)		
Hepatocholangiocarcinoma, Metastatic, Liver	1 (14%)			
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (25%)		
Oral Mucosa	(1)	(0)	(0)	(0)
Pancreas	(49)	(49)	(49)	(50)
Hepatocellular Carcinoma, Metastatic, Liver				1 (2%)
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(49)	(50)
Squamous Cell Papilloma	1 (2%)			
Stomach, Glandular	(48)	(49)	(49)	(50)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Tooth	(14)	(14)	(14)	(6)

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(49)	(48)	(44)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Heart	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Hemangioma		1 (2%)		
Hemangiosarcoma			2 (4%)	
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Epicardium, Carcinoma, Metastatic, Uncertain Primary Site		1 (2%)	1 (2%)	

ENDOCRINE SYSTEM

Adrenal Cortex	(49)	(50)	(49)	(49)
Adenoma		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Capsule, Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			
Subcapsular, Adenoma	4 (8%)		2 (4%)	
Zona Fasciculata, Adenoma			1 (2%)	
Adrenal Medulla	(49)	(50)	(46)	(49)
Pheochromocytoma Benign			1 (2%)	
Islets, Pancreatic	(49)	(49)	(49)	(50)
Adenoma			1 (2%)	
Parathyroid Gland	(27)	(32)	(26)	(33)
Pituitary Gland	(49)	(49)	(48)	(50)
Pars Distalis, Adenoma			2 (4%)	
Thyroid Gland	(49)	(49)	(48)	(49)
C-cell, Carcinoma		1 (2%)		
Follicular Cell, Adenoma			1 (2%)	
Follicular Cell, Carcinoma			1 (2%)	

GENERAL BODY SYSTEM

Peritoneum	(0)	(0)	(0)	(1)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (100%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
GENITAL SYSTEM				
Epididymis	(50)	(50)	(50)	(50)
Fibrosarcoma			1 (2%)	
Hepatocarcinoma, Metastatic, Liver	1 (2%)			
Preputial Gland	(50)	(50)	(49)	(50)
Prostate	(49)	(50)	(49)	(50)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Seminal Vesicle	(49)	(50)	(49)	(50)
Adenoma	1 (2%)			
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Testes	(49)	(49)	(50)	(50)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
HEMATOPOIETIC SYSTEM				
Bone Marrow	(49)	(50)	(48)	(50)
Hemangiosarcoma, Metastatic, Lymph Node		1 (2%)		
Hemangiosarcoma, Metastatic, Spleen	1 (2%)			
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Lymph Node	(2)	(2)	(2)	(2)
Hemangiosarcoma		1 (50%)		
Iliac, Hemangiosarcoma			1 (50%)	
Pancreatic, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (50%)
Lymph Node, Bronchial	(30)	(43)	(47)	(41)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		3 (7%)	1 (2%)	5 (12%)
Hemangiosarcoma, Metastatic, Heart			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (3%)			1 (2%)
Hepatocarcinoma, Metastatic, Liver	1 (3%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Lymph Node, Mandibular	(27)	(26)	(28)	(26)
Lymph Node, Mediastinal	(37)	(45)	(48)	(49)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (4%)	3 (6%)	4 (8%)
Carcinoma, Metastatic, Uncertain Primary Site			1 (2%)	
Hemangiosarcoma, Metastatic, Heart			1 (2%)	
Hemangiosarcoma, Metastatic, Spleen			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (3%)			2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (3%)			
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Lymph Node, Mesenteric	(48)	(47)	(47)	(50)
Fibrous Histiocytoma, Metastatic, Skin				1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Spleen	(49)	(50)	(50)	(50)
Hemangiosarcoma	2 (4%)		1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Plasma Cell Tumor Malignant		1 (2%)		
Thymus	(41)	(38)	(43)	(39)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (5%)		3 (8%)
Hemangiosarcoma, Metastatic, Heart			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (3%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
INTEGUMENTARY SYSTEM				
Mammary Gland	(0)	(2)	(4)	(1)
Skin	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Fibrosarcoma			2 (4%)	
Fibrous Histiocytoma		1 (2%)	1 (2%)	4 (8%)
Hemangioma		1 (2%)		
Sebaceous Gland, Carcinoma			1 (2%)	
Subcutaneous Tissue, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(49)	(50)
Hemangiosarcoma, Metastatic, Spleen			1 (2%)	
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Skeletal Muscle	(2)	(3)	(1)	(1)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (100%)
Hepatocarcinoma, Metastatic, Liver	1 (50%)			
Rhabdomyosarcoma		1 (33%)		
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Peripheral Nerve	(1)	(1)	(0)	(0)
Spinal Cord	(1)	(2)	(0)	(0)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
RESPIRATORY SYSTEM				
Larynx	(50)	(50)	(50)	(50)
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	7 (14%)	11 (22%)	7 (14%)	10 (20%)
Alveolar/Bronchiolar Adenoma, Multiple	3 (6%)	3 (6%)	2 (4%)	4 (8%)
Alveolar/Bronchiolar Carcinoma	4 (8%)	13 (26%)	14 (28%)	16 (32%)
Alveolar/Bronchiolar Carcinoma, Multiple		5 (10%)	6 (12%)	11 (22%)
Hepatoblastoma, Metastatic, Liver	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)	3 (6%)	2 (4%)	5 (10%)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			
Plasma Cell Tumor Malignant, Metastatic, Spleen		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site			1 (2%)	
Nose	(50)	(49)	(49)	(50)
Glands, Adenocarcinoma				1 (2%)
Pleura	(0)	(0)	(0)	(2)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (50%)
Trachea	(49)	(50)	(50)	(50)
SPECIAL SENSES SYSTEM				
Eye	(48)	(49)	(47)	(50)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Retrolbulbar, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Harderian Gland	(49)	(50)	(50)	(50)
Adenoma	5 (10%)	5 (10%)	4 (8%)	3 (6%)
Adenoma, Multiple	1 (2%)	1 (2%)		
Carcinoma	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Hemangioma				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
URINARY SYSTEM				
Kidney	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)		1 (2%)	1 (2%)
Plasma Cell Tumor Malignant		1 (2%)		
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
Ureter	(1)	(0)	(0)	(0)
Urinary Bladder	(50)	(50)	(48)	(50)
Rhabdomyosarcoma, Metastatic, Skeletal Muscle		1 (2%)		
SYSTEMIC LESIONS				
Multiple Organ	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)	1 (2%)	3 (6%)	1 (2%)
Lymphoma Malignant	4 (8%)	4 (8%)	3 (6%)	6 (12%)
Mesothelioma Malignant				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE MALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
------------------	---------	---------	----------	----------

Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	45	45	46	46
Total Primary Neoplasms	86	111	109	119
Total Animals with Benign Neoplasms	37	38	38	37
Total Benign Neoplasms	54	56	58	52
Total Animals with Malignant Neoplasms	25	40	36	40
Total Malignant Neoplasms	32	55	51	67
Total Animals with Metastatic Neoplasms	5	9	11	14
Total Metastatic Neoplasms	20	38	24	36
Total Animals with Malignant Neoplasms Uncertain Primary Site		1	3	
Total Animals with Neoplasms Uncertain- Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
--------------------	---------	---------	----------	----------

Disposition Summary

Animals Initially In Study	60	60	60	60
Early Deaths				
Accidentally Killed	1			
Moribund Sacrifice	10	11	16	27
Natural Death	3	8	8	8
Survivors				
Terminal Sacrifice	36	31	26	15
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(46)	(41)	(44)	(45)
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Hepatocellular carcinoma, Metastatic, Liver		1 (2%)		
Intestine Large, Cecum	(47)	(44)	(48)	(47)
Hepatocellular carcinoma, Metastatic, Liver		1 (2%)		
Polyp Adenomatous				1 (2%)
Intestine Large, Colon	(47)	(47)	(49)	(47)
Intestine Large, Rectum	(44)	(46)	(48)	(47)
Intestine Small, Duodenum	(47)	(44)	(45)	(45)
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Hepatocellular carcinoma, Metastatic, Liver		1 (2%)		
Intestine Small, Ileum	(47)	(45)	(47)	(45)
Hemangiosarcoma		1 (2%)		
Intestine Small, Jejunum	(47)	(43)	(46)	(44)
Adenoma			1 (2%)	1 (2%)
Carcinoma		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Hemangioma			1 (2%)	
Hemangiosarcoma			1 (2%)	
Hepatocellular Adenoma	9 (18%)	9 (18%)	11 (22%)	15 (30%)
Hepatocellular Adenoma, Multiple	2 (4%)	5 (10%)	5 (10%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Hepatocellular Carcinoma	4 (8%)	10 (20%)	9 (18%)	3 (6%)
Hepatocellular Carcinoma, Multiple	2 (4%)	1 (2%)	3 (6%)	1 (2%)
Hepatocholangiocarcinoma	1 (2%)	2 (4%)		
Mesentery	(9)	(12)	(16)	(7)
Fibrosarcoma, Metastatic, Pancreas		1 (8%)		
Granulosa Cell Tumor Malignant, Metastatic, Ovary			1 (6%)	
Hepatocholangiocarcinoma, Metastatic, Liver		1 (8%)		
Lipoma	1 (11%)			
Pancreas	(50)	(50)	(50)	(50)
Fibrosarcoma		1 (2%)		
Hemangiosarcoma, Metastatic, Liver			1 (2%)	
Salivary Glands	(50)	(50)	(50)	(50)
Myxosarcoma	1 (2%)			
Stomach, Forestomach	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Squamous Cell Papilloma	1 (2%)			
Stomach, Glandular	(50)	(49)	(50)	(50)
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Tongue	(0)	(1)	(0)	(0)
Tooth	(0)	(2)	(2)	(1)

CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(48)	(47)	(46)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Heart	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)	1 (2%)	1 (2%)
Pericardium, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	1 (2%)

ENDOCRINE SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Adrenal Cortex	(50)	(50)	(50)	(50)
Adenoma		1 (2%)		
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Capsule, Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Capsule, Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Subcapsular, Adenoma	1 (2%)		1 (2%)	
Adrenal Medulla	(50)	(50)	(48)	(49)
Pheochromocytoma Benign		2 (4%)		3 (6%)
Islets, Pancreatic	(50)	(49)	(49)	(49)
Adenoma		1 (2%)	1 (2%)	1 (2%)
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Parathyroid Gland	(27)	(33)	(34)	(32)
Adenoma				1 (3%)
Pituitary Gland	(49)	(50)	(50)	(50)
Pars Distalis, Adenoma	9 (18%)	10 (20%)	7 (14%)	3 (6%)
Pars Distalis, Carcinoma			1 (2%)	
Pars Intermedia, Adenoma		1 (2%)	1 (2%)	
Thyroid Gland	(48)	(50)	(50)	(50)
Follicular Cell, Adenoma				1 (2%)
Follicular Cell, Carcinoma			1 (2%)	

GENERAL BODY SYSTEM

Peritoneum	(0)	(0)	(1)	(0)
------------	-----	-----	-----	-----

GENITAL SYSTEM

Clitoral Gland	(48)	(44)	(47)	(42)
Ovary	(50)	(49)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Cystadenoma	1 (2%)	2 (4%)	2 (4%)	
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Granulosa Cell Tumor Malignant	1 (2%)		1 (2%)	
Granulosa-Theca Tumor Malignant		1 (2%)		
Hemangioma		1 (2%)		1 (2%)
Hemangiosarcoma	1 (2%)		1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Luteoma		1 (2%)		
Oviduct	(1)	(0)	(0)	(0)
Uterus	(50)	(50)	(50)	(50)
Carcinoma			1 (2%)	
Granular Cell Tumor Benign	1 (2%)			
Hemangiosarcoma	1 (2%)		1 (2%)	
Leiomyoma		2 (4%)		
Polyp Stromal	4 (8%)	2 (4%)	1 (2%)	2 (4%)
Endometrium, Polyp Stromal				1 (2%)

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Mast Cell Tumor Nos, Metastatic, Uncertain Primary Site				1 (2%)
Lymph Node	(6)	(9)	(14)	(16)
Hemangioma				1 (6%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (11%)		
Lumbar, Hemangiosarcoma	1 (17%)			
Lumbar, Hepatocholangiocarcinoma, Metastatic, Liver		1 (11%)		
Pancreatic, Fibrosarcoma, Metastatic, Pancreas		1 (11%)		
Pancreatic, Granulosa Cell Tumor Malignant, Metastatic, Ovary			1 (7%)	
Pancreatic, Hepatocholangiocarcinoma, Metastatic, Liver		1 (11%)		
Lymph Node, Bronchial	(41)	(47)	(48)	(49)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (4%)	2 (4%)	
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Lymph Node, Mandibular	(41)	(28)	(38)	(39)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Lymph Node, Mediastinal	(46)	(48)	(49)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (4%)	2 (4%)	
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Lymph Node, Mesenteric	(50)	(48)	(48)	(46)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Fibrosarcoma, Metastatic, Pancreas		1 (2%)		
Hemangiosarcoma				1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Spleen	(50)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)		
Thymus	(47)	(49)	(49)	(49)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (4%)		1 (2%)
Hemangioma				1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Thymoma Nos	1 (2%)			
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(50)	(50)	(50)
Carcinoma	1 (2%)	2 (4%)		
Squamous Cell Carcinoma, Metastatic, Skin				1 (2%)
Skin	(50)	(50)	(50)	(50)
Fibrosarcoma	1 (2%)	1 (2%)		1 (2%)
Fibrous Histiocytoma	1 (2%)			
Hemangiosarcoma	1 (2%)	1 (2%)		1 (2%)
Hemangiosarcoma, Metastatic, Liver			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Squamous Cell Carcinoma				2 (4%)
MUSCULOSKELETAL SYSTEM				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
Bone	(50)	(50)	(49)	(50)
Femur, Periosteum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Skeletal Muscle	(4)	(1)	(4)	(3)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (33%)
Carcinoma, Metastatic, Mammary Gland		1 (100%)		
Granulosa Cell Tumor Malignant, Metastatic, Ovary			1 (25%)	

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Peripheral Nerve	(3)	(0)	(2)	(1)
Spinal Cord	(4)	(0)	(2)	(1)

RESPIRATORY SYSTEM

Larynx	(50)	(50)	(50)	(50)
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	1 (2%)	7 (14%)	16 (32%)	7 (14%)
Alveolar/Bronchiolar Adenoma, Multiple		3 (6%)	3 (6%)	1 (2%)
Alveolar/Bronchiolar Carcinoma	2 (4%)	7 (14%)	5 (10%)	7 (14%)
Alveolar/Bronchiolar Carcinoma, Multiple		7 (14%)	6 (12%)	4 (8%)
Carcinoma, Metastatic, Harderian Gland	1 (2%)			
Granulosa-Theca Tumor Malignant, Metastatic, Ovary		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver	3 (6%)	3 (6%)		1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Mast Cell Tumor Nos, Metastatic, Uncertain Primary Site				1 (2%)
Nose	(50)	(49)	(50)	(50)
Pleura	(0)	(2)	(0)	(2)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (50%)		
Trachea	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
--------------------	---------	---------	----------	----------

SPECIAL SENSES SYSTEM

Ear	(0)	(0)	(0)	(1)
Eye	(49)	(47)	(49)	(49)
Harderian Gland	(49)	(50)	(50)	(50)
Adenoma	3 (6%)	4 (8%)	6 (12%)	2 (4%)
Carcinoma	4 (8%)			2 (4%)
Zymbal's Gland	(0)	(0)	(0)	(1)
Carcinoma				1 (100%)

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)	1 (2%)	1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)			
Urinary Bladder	(50)	(50)	(50)	(50)
Hemangioma		1 (2%)		

SYSTEMIC LESIONS

Multiple Organ	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	3 (6%)	6 (12%)	2 (4%)	3 (6%)
Lymphoma Malignant	7 (14%)	17 (34%)	20 (40%)	27 (54%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Antimony trioxide

Time Report Requested: 09:59:55

Route: RESPIRATORY EXPOSURE WHOLE BODY

CAS Number: 1309-64-4

First Dose M/F: 10/06/08 / 10/06/08

Species/Strain: MICE/B6C3F1

Lab: BNW

B6C3F1 MICE FEMALE	Control	3 mg/m3	10 mg/m3	30 mg/m3
--------------------	---------	---------	----------	----------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	35	47	46	45
Total Primary Neoplasms	66	111	108	97
Total Animals with Benign Neoplasms	25	35	35	31
Total Benign Neoplasms	33	52	56	44
Total Animals with Malignant Neoplasms	25	40	35	41
Total Malignant Neoplasms	32	59	52	53
Total Animals with Metastatic Neoplasms	7	13	5	7
Total Metastatic Neoplasms	8	47	13	15
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain- Benign or Malignant	1			
Total Uncertain Neoplasms	1			

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors